AAPL348.91+5.08 (+1.48%) ▲|ABBV290.79+4.80 (+1.68%) ▲|ABT104.57+1.93 (+1.88%) ▲|ACN247.22+3.82 (+1.57%) ▲|ADBE248.12-1.64 (-0.66%) ▼|AMAT421.66+5.66 (+1.36%) ▲|AMD566.42-12.02 (-2.08%) ▼|AMGN460.73+8.90 (+1.97%) ▲|AMT185.88+2.13 (+1.16%) ▲|AMZN243.79-10.81 (-4.25%) ▼|AVGO345.00-6.81 (-1.94%) ▼|AXP323.71+5.77 (+1.81%) ▲|BA172.65+5.51 (+3.30%) ▲|BAC51.14+0.29 (+0.57%) ▲|BKNG150.43+2.49 (+1.68%) ▲|BLK1,176.24+18.36 (+1.59%) ▲|BMY61.39+0.82 (+1.35%) ▲|BNY149.37+0.78 (+0.52%) ▲|BRK-B541.96+1.62 (+0.30%) ▲|C125.76+1.65 (+1.33%) ▲|CAT647.39-65.99 (-9.25%) ▼|CL93.16+1.47 (+1.60%) ▲|CMCSA22.27+0.70 (+3.25%) ▲|COF208.74+3.86 (+1.88%) ▲|COP150.03+0.97 (+0.65%) ▲|COST996.08+13.35 (+1.36%) ▲|CRM230.90-11.21 (-4.63%) ▼|CSCO108.59-1.70 (-1.54%) ▼|CVS90.33+0.38 (+0.42%) ▲|CVX231.46+2.26 (+0.99%) ▲|DE660.00+19.33 (+3.02%) ▲|DHR236.98+2.91 (+1.24%) ▲|DIS110.91+1.87 (+1.72%) ▲|DUK125.90+2.33 (+1.89%) ▲|EMR170.74+3.03 (+1.81%) ▲|FDX307.82+3.24 (+1.06%) ▲|GD370.82+16.47 (+4.65%) ▲|GE313.05+11.92 (+3.96%) ▲|GEV887.85+9.82 (+1.12%) ▲|GILD165.61+6.41 (+4.03%) ▲|GM85.72+3.24 (+3.93%) ▲|GOOG282.32-39.57 (-12.29%) ▼|GOOGL283.82-41.07 (-12.64%) ▼|GS927.73+2.56 (+0.28%) ▲|HD328.98+11.42 (+3.60%) ▲|HON222.14+2.88 (+1.31%) ▲|IBM258.28+5.06 (+2.00%) ▲|INTC92.07-3.46 (-3.62%) ▼|INTU331.19+3.00 (+0.91%) ▲|ISRG448.76+4.58 (+1.03%) ▲|JNJ275.20+4.16 (+1.53%) ▲|JPM343.58+4.28 (+1.26%) ▲|KO92.82+1.09 (+1.19%) ▲|LIN503.15-5.01 (-0.99%) ▼|LLY1,373.70+85.40 (+6.63%) ▲|LMT643.59+13.84 (+2.20%) ▲|LOW207.28+8.88 (+4.48%) ▲|LRCX254.39+0.57 (+0.22%) ▲|MA635.70+25.39 (+4.16%) ▲|MCD257.38+6.88 (+2.75%) ▲|MDLZ62.53+0.66 (+1.07%) ▲|MDT97.11+2.33 (+2.46%) ▲|META624.52+12.03 (+1.96%) ▲|MMM177.36+4.56 (+2.64%) ▲|MO76.75+3.76 (+5.15%) ▲|MRK146.33+5.40 (+3.83%) ▲|MS190.00-0.13 (-0.07%) ▼|MSFT530.14-0.87 (-0.16%) ▼|MU934.27-48.96 (-4.98%) ▼|NEE82.14+1.12 (+1.38%) ▲|NFLX62.05+0.06 (+0.10%) ▲|NKE38.42+1.27 (+3.42%) ▲|NOW109.67-40.46 (-26.95%) ▼|NVDA213.66-1.72 (-0.80%) ▼|ORCL139.56-4.98 (-3.45%) ▼|PEP133.79+1.16 (+0.87%) ▲|PFE29.95+0.50 (+1.70%) ▲|PG160.59+2.33 (+1.47%) ▲|PLTR196.42-0.39 (-0.20%) ▼|PM208.50+5.86 (+2.89%) ▲|QCOM185.41+2.44 (+1.33%) ▲|RTX199.40+3.56 (+1.82%) ▲|SBUX105.51+2.31 (+2.24%) ▲|SCHW89.47+0.71 (+0.80%) ▲|SO92.99+1.47 (+1.61%) ▲|SPG215.72+4.48 (+2.12%) ▲|T20.92+0.22 (+1.06%) ▲|TMO709.18+5.03 (+0.71%) ▲|TMUS147.29-0.79 (-0.53%) ▼|TSLA403.30-0.92 (-0.23%) ▼|TXN312.94+3.11 (+1.00%) ▲|UBER65.74+0.47 (+0.72%) ▲|UNH410.91+3.81 (+0.94%) ▲|UNP301.93+4.13 (+1.39%) ▲|UPS107.33+1.71 (+1.62%) ▲|USB60.64+1.04 (+1.75%) ▲|V410.54+9.94 (+2.48%) ▲|VZ43.66+0.48 (+1.11%) ▲|WFC84.81+1.14 (+1.36%) ▲|WMT121.25+2.48 (+2.09%) ▲|XOM183.29+1.27 (+0.70%) ▲|AAPL348.91+5.08 (+1.48%) ▲|ABBV290.79+4.80 (+1.68%) ▲|ABT104.57+1.93 (+1.88%) ▲|ACN247.22+3.82 (+1.57%) ▲|ADBE248.12-1.64 (-0.66%) ▼|AMAT421.66+5.66 (+1.36%) ▲|AMD566.42-12.02 (-2.08%) ▼|AMGN460.73+8.90 (+1.97%) ▲|AMT185.88+2.13 (+1.16%) ▲|AMZN243.79-10.81 (-4.25%) ▼|AVGO345.00-6.81 (-1.94%) ▼|AXP323.71+5.77 (+1.81%) ▲|BA172.65+5.51 (+3.30%) ▲|BAC51.14+0.29 (+0.57%) ▲|BKNG150.43+2.49 (+1.68%) ▲|BLK1,176.24+18.36 (+1.59%) ▲|BMY61.39+0.82 (+1.35%) ▲|BNY149.37+0.78 (+0.52%) ▲|BRK-B541.96+1.62 (+0.30%) ▲|C125.76+1.65 (+1.33%) ▲|CAT647.39-65.99 (-9.25%) ▼|CL93.16+1.47 (+1.60%) ▲|CMCSA22.27+0.70 (+3.25%) ▲|COF208.74+3.86 (+1.88%) ▲|COP150.03+0.97 (+0.65%) ▲|COST996.08+13.35 (+1.36%) ▲|CRM230.90-11.21 (-4.63%) ▼|CSCO108.59-1.70 (-1.54%) ▼|CVS90.33+0.38 (+0.42%) ▲|CVX231.46+2.26 (+0.99%) ▲|DE660.00+19.33 (+3.02%) ▲|DHR236.98+2.91 (+1.24%) ▲|DIS110.91+1.87 (+1.72%) ▲|DUK125.90+2.33 (+1.89%) ▲|EMR170.74+3.03 (+1.81%) ▲|FDX307.82+3.24 (+1.06%) ▲|GD370.82+16.47 (+4.65%) ▲|GE313.05+11.92 (+3.96%) ▲|GEV887.85+9.82 (+1.12%) ▲|GILD165.61+6.41 (+4.03%) ▲|GM85.72+3.24 (+3.93%) ▲|GOOG282.32-39.57 (-12.29%) ▼|GOOGL283.82-41.07 (-12.64%) ▼|GS927.73+2.56 (+0.28%) ▲|HD328.98+11.42 (+3.60%) ▲|HON222.14+2.88 (+1.31%) ▲|IBM258.28+5.06 (+2.00%) ▲|INTC92.07-3.46 (-3.62%) ▼|INTU331.19+3.00 (+0.91%) ▲|ISRG448.76+4.58 (+1.03%) ▲|JNJ275.20+4.16 (+1.53%) ▲|JPM343.58+4.28 (+1.26%) ▲|KO92.82+1.09 (+1.19%) ▲|LIN503.15-5.01 (-0.99%) ▼|LLY1,373.70+85.40 (+6.63%) ▲|LMT643.59+13.84 (+2.20%) ▲|LOW207.28+8.88 (+4.48%) ▲|LRCX254.39+0.57 (+0.22%) ▲|MA635.70+25.39 (+4.16%) ▲|MCD257.38+6.88 (+2.75%) ▲|MDLZ62.53+0.66 (+1.07%) ▲|MDT97.11+2.33 (+2.46%) ▲|META624.52+12.03 (+1.96%) ▲|MMM177.36+4.56 (+2.64%) ▲|MO76.75+3.76 (+5.15%) ▲|MRK146.33+5.40 (+3.83%) ▲|MS190.00-0.13 (-0.07%) ▼|MSFT530.14-0.87 (-0.16%) ▼|MU934.27-48.96 (-4.98%) ▼|NEE82.14+1.12 (+1.38%) ▲|NFLX62.05+0.06 (+0.10%) ▲|NKE38.42+1.27 (+3.42%) ▲|NOW109.67-40.46 (-26.95%) ▼|NVDA213.66-1.72 (-0.80%) ▼|ORCL139.56-4.98 (-3.45%) ▼|PEP133.79+1.16 (+0.87%) ▲|PFE29.95+0.50 (+1.70%) ▲|PG160.59+2.33 (+1.47%) ▲|PLTR196.42-0.39 (-0.20%) ▼|PM208.50+5.86 (+2.89%) ▲|QCOM185.41+2.44 (+1.33%) ▲|RTX199.40+3.56 (+1.82%) ▲|SBUX105.51+2.31 (+2.24%) ▲|SCHW89.47+0.71 (+0.80%) ▲|SO92.99+1.47 (+1.61%) ▲|SPG215.72+4.48 (+2.12%) ▲|T20.92+0.22 (+1.06%) ▲|TMO709.18+5.03 (+0.71%) ▲|TMUS147.29-0.79 (-0.53%) ▼|TSLA403.30-0.92 (-0.23%) ▼|TXN312.94+3.11 (+1.00%) ▲|UBER65.74+0.47 (+0.72%) ▲|UNH410.91+3.81 (+0.94%) ▲|UNP301.93+4.13 (+1.39%) ▲|UPS107.33+1.71 (+1.62%) ▲|USB60.64+1.04 (+1.75%) ▲|V410.54+9.94 (+2.48%) ▲|VZ43.66+0.48 (+1.11%) ▲|WFC84.81+1.14 (+1.36%) ▲|WMT121.25+2.48 (+2.09%) ▲|XOM183.29+1.27 (+0.70%) ▲|
15.3 C
New York
Friday, October 30, 2026

Tag: years

newsFORsourcecompanycontentinformationreleases1market

Revision Skincare® Appoints Marco Ficarelli as Chief Global Growth Officer

DALLAS, June 26, 2026 /PRNewswire/ -- Revision Skincare®, a physician-dispensed, clinically validated skincare brand focused on long-term skin health and medical-grade skincare for everyday use,...

After more than four decades of exceptional leadership and contribution to the fragrance industry, we announce the retirement of Jack Corley, Chief Sales and...

SOMERSET, N.J. , June 26, 2026 /PRNewswire/ -- Jack's career spans 45 years and is marked by a rare combination of commercial excellence, industry expertise,...

Winners Announced at 31st Shanghai TV Festival Magnolia Awards

SHANGHAI, June 26, 2026 /PRNewswire/ -- The 31st Shanghai TV Festival Magnolia Awards ceremony was held tonight, celebrating outstanding achievements in television. This year's...

Minister Anandasangaree highlights launch of National Food Security Strategy

SCARBOROUGH, ON, June 26, 2026 /CNW/ - The Government of Canada is focused on building a stronger economy and making life more affordable for...

Milei opens up to Ismael Cala: Childhood traumas, the Torah, and the fall of Cuba

EXCLUSIVE INTERVIEWIn a historic and extensive interview lasting over an hour with journalist Ismael Cala, the President of the Argentine Republic strips away his...

Milei opens up to Ismael Cala: Childhood traumas, the Torah, and the fall of Cuba

EXCLUSIVE INTERVIEWIn a historic and extensive interview lasting over an hour with journalist Ismael Cala, the President of the Argentine Republic strips away his...

Blue Lizard® Brand Sunscreen Named First Official Sunscreen Partner of the Manning Passing Academy

A Partnership to Showcase the Importance of Sun Safety On and Off the FieldNASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Revance is proud to...

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

University of Phoenix Launches Three New Artificial Intelligence Professional Development Pathways

New offerings help employees, senior leaders and healthcare professionals build practical AI skills for workplace application, governance and healthcare settingsPHOENIX, June 26, 2026 /PRNewswire/...

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

FEDERAL-PROVINCIAL-TERRITORIAL MEETING – Ministers Responsible for Canadian Francophonie Review Progress and Future Prospects

WINNIPEG, MB, June 26, 2026 /CNW/ - Under the theme Let's Celebrate the Francophonie at the Heart of Canada, the Ministers' Council on the Canadian Francophonie...

FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Health

If finalized, rule would level the playing field between American and foreign businesses 
If finalized, rule would level the playing field between American and foreign businesses

Mesirow Advises StrategIQ Commerce on its Sale to Loop

StrategIQ Commerce is a market-leading provider of real-time data and visibility solutions for supply chain management, focusing on auditing, customized KPI reporting, and predictive...

FIA Delivers Strongest Set of Financial Results in a Decade

FIA posts best financial results in a decade: €6.7M operating profit in 2025, revenues of €191.7M, and cash doubled to €43.6M

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsYears

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers